Zymeworks Inc.

NasdaqGS:ZYME Stock Report

Market Cap: US$973.2m

Zymeworks Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Ken Galbraith

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage18.5%
CEO tenure3yrs
CEO ownership0.1%
Management average tenure2yrs
Board average tenure1.7yrs

Recent management updates

Recent updates

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Dec 19

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Dec 13
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Nov 08
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Nov 04

Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Nov 03
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Nov 01
Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 27

Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Aug 07
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week

Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Jul 26
Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up

Zymeworks: A Somewhat Complicated Story

Jul 09

Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Jun 12
Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans

Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

May 03
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business

Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data

Apr 18

Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments

Mar 05

Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion

Feb 06

Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind

Jan 31

Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M

Nov 08

Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone

Oct 26

CEO Compensation Analysis

How has Ken Galbraith's remuneration changed compared to Zymeworks's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$114m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$3mUS$625k

-US$119m

Sep 30 2023n/an/a

US$205m

Jun 30 2023n/an/a

US$186m

Mar 31 2023n/an/a

US$173m

Dec 31 2022US$7mUS$582k

US$124m

Sep 30 2022n/an/a

-US$224m

Jun 30 2022n/an/a

-US$237m

Mar 31 2022n/an/a

-US$240m

Dec 31 2021n/an/a

-US$212m

Sep 30 2021n/an/a

-US$211m

Jun 30 2021n/an/a

-US$223m

Mar 31 2021n/an/a

-US$194m

Dec 31 2020n/an/a

-US$181m

Sep 30 2020n/an/a

-US$215m

Jun 30 2020n/an/a

-US$173m

Mar 31 2020n/an/a

-US$163m

Dec 31 2019US$167kn/a

-US$145m

Compensation vs Market: Ken's total compensation ($USD3.37M) is about average for companies of similar size in the US market ($USD3.22M).

Compensation vs Earnings: Ken's compensation has been consistent with company performance over the past year.

CEO

Ken Galbraith (61 yo)

3yrs

Tenure

US$3,374,876

Compensation

Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...

Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Galbraith
Chairman of the Board3yrsUS$3.37m0.12%
$ 1.1m
Paul Moore
Chief Scientific Officer2.5yrsUS$1.68m0.034%
$ 329.7k
Leone Patterson
Executive VP and Chief Business & Financial Officerless than a yearno datano data
Mark Hollywood
Executive VP and Head of Technical & Manufacturing Operationsno datano datano data
Shrinal Inamdar
Director of Investor Relationsno datano datano data
Daniel Dex
Senior VPno datano datano data
Diana Papove
Senior Manager of Corporate Communicationsno datano datano data
Lindsey Foulkes
Vice President of Corporate Developmentno datano datano data
Laura O'Connor
Vice President of Human Resources & DEI2yrsno datano data
Jeffrey Smith
Executive VP & Chief Medical Officerno datano datano data
John Fann
Senior Vice President of Process Sciencesless than a yearno datano data
Ryan Dercho
Senior Director of Corporate Affairsno datano datano data

2.0yrs

Average Tenure

61yo

Average Age

Experienced Management: ZYME's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kenneth Galbraith
Chairman of the Board3yrsUS$3.37m0.12%
$ 1.1m
Nancy Davidson
Independent Director1.1yrsUS$441.02k0%
$ 0
Neil Gallagher
Independent Directorless than a yearno data0%
$ 0
Kelvin Neu
Independent Director4.8yrsUS$262.46k0%
$ 0
Susan Mahony
Lead Independent Director5.6yrsUS$261.83k0%
$ 0
Alessandra Cesano
Independent Directorless than a yearno data0%
$ 0
Derek John Miller
Independent Director1.8yrsUS$555.15k0%
$ 0
Troy Cox
Independent Director5.6yrsUS$263.83k0.011%
$ 106.0k
Scott Platshon
Independent Directorless than a yearno datano data
Carlos Campoy
Independent Director1.6yrsUS$508.97k0%
$ 0
Troy Cox
no datano datano data

1.7yrs

Average Tenure

60yo

Average Age

Experienced Board: ZYME's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:25
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Zymeworks Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Arlinda LeeCanaccord Genuity
Yigal NochomovitzCitigroup Inc